论文部分内容阅读
目的 观察特异性溶栓药重组葡激酶(recombinant staphylokinase,r-Sak)治疗实验性视网膜中央静脉阻塞(central retinal vein occlusion,CRVO)的效果及其对全身的影响。方法 21只兔42眼以光化学法建立CRVO模型,静注r-Sak、尿激酶(urokinase,UK)溶栓,观察血管再通情况及其对循环系统的影响。结果 r-Sak组在用药4h后的完全再通率为92.86％,而UK组的完全再通率仅为50％。使用r-Sak后血液中凝血、纤溶、抗纤溶指标变化较小。结论 r-Sak是一种高效、特异性强的溶栓药,在临床上有较好的应用前景。
Objective To observe the effect of systemic fibrinolysis on specific retinal vein occlusion (CRVO) treated with recombinant staphylokinase (r-Sak). Methods Twenty-one eyes of 42 rabbits were randomly divided into three groups. The CRVO model was established by photochemical method. Thrombolytic therapy with r-Sak and urokinase (UK) was performed intravenously to observe the vascular recanalization and its effects on the circulatory system. Results In the r-Sak group, the complete recanalization rate after 4 h was 92.86%, while the complete recanalization rate in the UK group was only 50%. After using r-Sak blood coagulation, fibrinolysis, anti-fibrinolysis changes smaller. Conclusion r-Sak is a highly efficient and specific thrombolytic agent, which has a good clinical application.